Heart Failure Patients With COVID-19 Nearly Twice as Likely to Die and at Triple the Risk of Intubation Compared to Those Without Pre-Existing Heart Condition

Results may lead to closer monitoring of heart failure patients in hospital and at home


Journal: Journal of the American College of Cardiology

Title: “Prognostic Impact of Prior Heart Failure in Patients Hospitalized with COVID-19”

Authors: Anu Lala, MD, Assistant Professor of Medicine (Cardiology) at the Icahn School of Medicine at Mount Sinai

Jesus Alvarez-Garcia, MD, PhD, Postdoctoral Fellow in Advanced Heart Failure and Transplantation at the Icahn School of Medicine at Mount Sinai

Bottom Line: Mount Sinai researchers found that COVID-19 patients with a history of heart failure were associated with a longer duration of hospitalization, nearly three times the risk of intubation and mechanical ventilation, and double the risk of death, compared to those without a history of heart failure. 

What the Research Shows: This observational study shows COVID-19 patients with a history of heart failure, regardless of the type of heart failure they have, are associated with worse hospital outcomes when compared to COVID-19 patients with no history of heart failure. 

Why this is Interesting: Cardiovascular disease, including heart failure, has already been identified as a risk factor for worse outcomes in COVID-19, but this is one of the first studies that shows how much risk may be associated with this patient population, depending on their type of heart failure.  By showing just how strong the association is between all categories of heart failure, COVID-19, and an increased risk of severe complications, this may lead to quicker assessment of these patients after hospital admission and more aggressive therapy. Additionally, hospitals should take extra precautions to prevent exposure of COVID-19 for heart failure patients who have not tested positive for the virus.  Given the risk, researchers say it’s important for clinicians to rely on telemonitoring and telemedicine for heart failure patients to limit possible COVID-19 exposures in a medical office or hospital setting.

What Research Means for Doctors: The study may help with quicker assessment of heart failure patients when they’re admitted to the hospital with COVID-19 and could lead to more aggressive treatment. Additionally, researchers say clinicians treating heart failure patients without COVID-19 should take extra precautions to make sure patients are not exposed to the virus. They also suggest doctors should heavily rely on telemedicine and telemonitoring of heart failure patients when appropriate, which will also help limit exposure. 

What Research Means for Patients: This emphasizes the need for heart failure patients to be vigilant when it comes to protecting themselves during the COVID-19 pandemic. This includes social distancing, frequent hand-washing, wearing a mask, staying up to date on vaccinations including flu, and asking doctors about extra monitoring if necessary. Researchers suggest heart failure patients stay on top of their medication, and not change medications without talking to their doctors first.

How Research Was Conducted: Researchers looked at electronic medical records of 6,439 admitted and confirmed COVID-19-positive adult patients between February 27 and June 26, at Mount Sinai Health System hospitals422 patients had a previous history of heart failure and researchers classified them into three groups based on left ventricle ejection fraction or “EF,” which represents the percentage of blood the left ventricle pumps with each contraction and helps to classify the type of heart failure.  Specific categories were “heart failure with reduced EF,” “heart failure with mid-range EF,” and “heart failure with preserved EF.” They analyzed differences among all patients (with and without heart failure) including length of hospital stay, intubation and mechanical ventilation, and morbidity.  Researchers adjusted for different factors such as age, race, hypertension, diabetes, and renal disease.


Jesus Alvarez-Garcia, MD, PhD: “In this study, it was surprising and particularly interesting to note the lack of difference in outcomes among patients with heart failure according to their type.  Additionally, at the beginning of the pandemic, some heart failure drugs were believed to lead to increased risk of worse outcomes for COVID-19 patients, but our analysis shows no association between heart failure drugs, specifically angiotensin inhibitors, and worse prognosis. This study reinforces that these medications should be maintained unless healthcare providers recommend stopping them in specific cases.”

Anu Lala, MD: “To date, little has been published on the implications of a history of heart failure on outcomes among patients hospitalized with COVID-19. We expected an association with worse outcomes but not to this degree. A two-fold difference in mortality after adjusting for other factors regardless of ejection fraction makes me think we should think about triage of these patients carefully. It also makes me more cautious in reminding patients of the importance of good hygiene and mask-wearing to prevent the contraction of COVID-19 even during routine ambulatory heart failure visits.”

About the Mount Sinai Health System

The Mount Sinai Health System is New York City's largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. Mount Sinai Heart at The Mount Sinai Hospital is the nation’s No. 6-ranked heart center, and The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report's "Honor Roll" of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.



Filters close

Showing results

110 of 4156
Newswise: Stimulus Relief Funds Increase Social Distancing to Stop Spread of COVID-19
23-Nov-2020 5:20 PM EST
Stimulus Relief Funds Increase Social Distancing to Stop Spread of COVID-19
University of California San Diego

As case rates of COVID-19 reach new heights across the nation, many states and cities are tightening stay-at-home restrictions to stop the spread. New research suggests that that those suffering from economic hardships are less likely comply with new stay-at-home orders; however these same U.S. residents would be more likely to adhere to the new public health guidelines if their households received stimulus funds.

access_time Embargo lifts in 2 days
Embargo will expire: 1-Dec-2020 9:15 AM EST Released to reporters: 30-Nov-2020 2:30 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 1-Dec-2020 9:15 AM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise:Video Embedded covid-19-update-surge-preparedness-vaccine-distribution
Released: 30-Nov-2020 2:20 PM EST
COVID-19 Update: Surge Preparedness, Vaccine Distribution

With the novel coronavirus spreading across the U.S. at a record pace, Cedars-Sinai has been seeing an increase in COVID-19 patients at its hospitals and through its network of physicians. But the health system's leaders say Cedars-Sinai is prepared.

Released: 30-Nov-2020 1:20 PM EST
Rethink COVID-19 infection control to keep primary schools open this winter, governments urged

An urgent rethink of infection control policies to keep COVID-19 infection at bay in schools is needed if primary schools are to be kept open this winter, and the knock-on effects on their families avoided, argue children's infectious disease specialists in a viewpoint, published online in the Archives of Disease in Childhood.

Newswise: Hackensack University Medical Center Urologists Continue to Provide State-of-the-Art Care During COVID-19
Released: 30-Nov-2020 12:45 PM EST
Hackensack University Medical Center Urologists Continue to Provide State-of-the-Art Care During COVID-19
Hackensack Meridian Health

Don’t Delay Your Care – Our dnhanced pandemic safety precautions prioritize patient health and allow providers to deliver outstanding in-office, telehealth and surgical care

Released: 30-Nov-2020 12:10 PM EST
Struggles of care home staff during COVID-19 first wave revealed in Whatsapp messages
University of Leeds

Analysis of social media messages between care home staff on the coronavirus front line reveal their growing concerns over how to manage in the face of the virus.

Released: 30-Nov-2020 11:30 AM EST
More than one-third of children with COVID-19 show no symptoms: study
University of Alberta Faculty of Medicine & Dentistry

More than one-third of kids who have COVID-19 are asymptomatic, according to a University of Alberta study that suggests youngsters diagnosed with the disease may represent just a fraction of those infected.

Newswise: Promising lab results in quest to find naturally occurring anti-COVID therapies
24-Nov-2020 5:35 PM EST
Promising lab results in quest to find naturally occurring anti-COVID therapies
University of Alabama Huntsville

So far, 35 of 125 naturally occurring compounds identified computationally at The University of Alabama in Huntsville (UAH) to have potential against COVID-19 have shown efficacy in ongoing first-batch testing at the University of Tennessee Health Science Center’s Regional Biocontainment Laboratory (UTHSC RBL) that’s the next step in the process to becoming a drug.

Released: 30-Nov-2020 9:45 AM EST
Rutgers Leading Coronavirus Therapeutic Clinical Trial
Rutgers University-New Brunswick

Rutgers is leading a clinical trial assessing the efficacy of a three-drug combination in treating people infected with SARS-CoV-2 and asymptomatic or mildly symptomatic.

Showing results

110 of 4156